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Figure Two. Gene expression is present in the control and MCD 
groups with high CBG, the gene expression decreased in the 
control and MCD groups with low CBG. D. Shows the % of 
Fibrosis in the α-SMA stain. E. Shows the gene expression in 
the α-SMA.
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Conclusion
• The gene expression of α-SMA increased 
in the control and MCD groups that 
received high CBG treatment and 
decreased in the mice that received low 
CBG treatment for both control and MCD 
groups.
• In the MCD group with vehicle, fibrosis is 
enhanced.
• Collagen deposition decreased with low 
dose of CBG, while high dose of CBG 
increased collagen when compared to 
MCD with vehicle.
Fibrosis was found to be decreased in 
the mice that received a low CBG dose 
demonstrated by the Sirius red and α-
SMA staining in the control and MCD 
group, but not in the mice that 
received a high dose of CBG.
To assess how CBG affects liver Fibrosis in an 
MCD-induced NASH mice model.
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Methods
• 7–8-week-old male and female C57BL/6 mice 
were fed with a MCD or matching control diet 
for a total of 5 weeks.
• Mice were I.P. injected with either vehicle, low 
dose (2.46 mg/kg/day), high dose (24.6 
mg/kg/day) of CBG at the last two weeks. 
• Liver fibrosis is evaluated with pico-Sirius red 
staining, the mRNA and protein levels of 
fibrosis biomarker, α-smooth muscle actin 
(SMA) by qRT-PCR, and immunofluorescence 
staining, respectively.
NASH is characterized with hepatic inflammation 
and fibrosis caused by the buildup of fat and 
other stimuli in the liver (two-hit theory). The 
MCD diet is known to induce non-alcoholic 
steatohepatitis (NASH) in a short period of time. 
When MCD diet is used, more fat is trapped in 
the liver. Currently no medicine is approved for 
NASH treatment. Therefore, finding promising 
agents to alleviate the NASH symptoms in 
patients is critically needed. Cannabigerol (CBG) 
is a non-psychoactive cannabinoid component 
that has anti-inflammatory effects in other 
studies. However, the effect of CBG on NASH is 
unknown. We hypothesized that liver fibrosis 
decreases with low dose of CBG administration 
in MCD induced NASH mice models.
Figure 1. low CBG shows 
a decrease in Fibrosis in 
both control and MCD, 
high CBG does not show 
a decrease in Fibrosis in 
both control and 
MCD. B. Shows the % of 
fibrosis in each group.
Future Direction
• Evaluate why a low dose of CBG 
decreases the expression of Fibrosis.
• Investigate what long term use of 
CBG has on the liver and on Fibrosis.
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